IP Library Granted Patent US 10,188,617
Granted Patent B2
US 10,188,617 · App. 14/774,623 · Granted Jan 29, 2019

Modulation of cellular DNA repair activity to intercept malignancy

Inventors: Elizabeth Alli (Winston-Salem, NC); James M. Ford (Mountain View, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
A61K31/18A61K31/165A61K31/64C12Q1/6886G01N21/6486C12Q2600/156C12Q2600/158Y02A50/473
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,188,617
App. No.
14/774,623
Granted
Jan 29, 2019
Kind
B2
Abstract

Disclosed herein are methods for identifying compounds that enhance base excision repair, as well as compounds identified thereby and methods of using such compounds in the interception of malignancy, i.e. the prevention of progression of a disease from a state of susceptibility to active disease. Exemplified compounds are acetohexamide and related compounds, as well as benserazide and analogs thereof. Exemplified malignancies are those of human breast cells carrying mutations, in particular, SUM149 cells and HCC1937 cells, which cells carry BRCA1 mutations.

Claims (15)

1. A method of reducing the risk of cancer in a subject having a mutation in BRCA1, comprising administering to said subject an effective amount of a DNA repair agent which is benserazide.

2. The method of claim 1 further comprising a step wherein a DNA repair assay is conducted on a cell from the subject.

3. The method of claim 1 further comprising the step of testing said subject for the presence of a BRCA1 mutation by determining a genotype of a normal somatic cell from said subject.

4. The method of claim 3 further comprising the step of testing a somatic cell from said subject for a level of base excision repair activity.

5. The method of claim 4 wherein said testing comprises transfecting the somatic cell with an oxidatively damaged vector that is expressed only after repair of oxidative damage by the cell.

6. The method of claim 1 , further comprising, prior to said administering, evaluating said subject by a base excision repair activity assay.

7. The method of claim 1 , further comprising measuring a level of oxidative DNA damage in a sample from said subject selected from the group consisting of: a cell sample, a urine sample, a serum sample, and a saliva sample.

8. The method of claim 1 wherein the cancer is breast cancer or ovarian cancer.

9. The method of claim 1 wherein the cancer is breast cancer.

10. The method of claim 1 , further comprising taking a family history from the subject.

11. The method of claim 10 , comprising taking a family history of first degree relatives from the subject.

12. The method of claim 11 , further comprising taking a family history of second degree relatives from the subject.

13. The method of claim 1 , wherein said administering is by oral administration.

14. The method of claim 1 , wherein said administering is by parenteral administration.

15. The method of claim 5 , wherein the vector is oxidatively damaged by photodynamic treatment.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2016
From: ALLI, ELIZABETH; FORD, JAMES MATTHEW
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 039969/0177 →
CONFIRMATORY LICENSE Recorded Jun 21, 2016
From: STANFORD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039094/0054 →
Continuity (2)
Provisional Application 61777659 · Mar 12, 2013
Related Publication 20160038444A1 · Feb 11, 2016